Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salvatore Perrone

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Expert Review of Hematology|October 22, 2022
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid TumoursMatteo Molica, Salvatore Perrone
Haematologica|October 12, 2012
The diagnostic role of galactomannan during antifungal prophylaxis. Comment on: "The role of antifungal treatment in hematology". Haematologica 2012;97(3):325-7Corrado Girmenia, Salvatore Perrone
Expert Review of Anticancer Therapy|January 3, 2025
Venetoclax and beyond: New Horizons in CLL and AML therapyMatteo Molica, Salvatore Perrone
Seminars in Thrombosis and Hemostasis|November 4, 2024
Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors DeficiencySalvatore Perrone, Simona Raso, Mariasanta Napolitano
Journal of Clinical Medicine|June 10, 2023
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat Matteo Molica, Salvatore Perrone, Marco Rossi
Leukemia Research|July 27, 2024
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysisMatteo Molica, Salvatore Perrone, Marco Rossi, et al.
Cancers|October 28, 2023
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in ProgressMatteo Molica, Salvatore Perrone, Costanza Andriola, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Salvatore Perrone, Tiziana Ottone, Nadezda Zhdanovskaya, et al.
Expert Opinion on Pharmacotherapy|May 28, 2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safetySalvatore Perrone, Fulvio Massaro, Giuliana Alimena, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 8, 2016
Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapySalvatore Perrone, Gianna Maria D'Elia, Giorgia Annechini, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Expert Review of Hematology|October 22, 2022
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid TumoursMatteo Molica, Salvatore Perrone
Haematologica|October 12, 2012
The diagnostic role of galactomannan during antifungal prophylaxis. Comment on: "The role of antifungal treatment in hematology". Haematologica 2012;97(3):325-7Corrado Girmenia, Salvatore Perrone
Expert Review of Anticancer Therapy|January 3, 2025
Venetoclax and beyond: New Horizons in CLL and AML therapyMatteo Molica, Salvatore Perrone
Seminars in Thrombosis and Hemostasis|November 4, 2024
Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors DeficiencySalvatore Perrone, Simona Raso, Mariasanta Napolitano
Journal of Clinical Medicine|June 10, 2023
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat Matteo Molica, Salvatore Perrone, Marco Rossi
Leukemia Research|July 27, 2024
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysisMatteo Molica, Salvatore Perrone, Marco Rossi, et al.
Cancers|October 28, 2023
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in ProgressMatteo Molica, Salvatore Perrone, Costanza Andriola, et al.
Cancer Drug Resistance (Alhambra, Calif.)|July 17, 2023
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?Salvatore Perrone, Tiziana Ottone, Nadezda Zhdanovskaya, et al.
Expert Opinion on Pharmacotherapy|May 28, 2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safetySalvatore Perrone, Fulvio Massaro, Giuliana Alimena, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 8, 2016
Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective TherapySalvatore Perrone, Gianna Maria D'Elia, Giorgia Annechini, et al.
Pageof 8